戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ited toward the discovery of a cocaine-abuse pharmacotherapeutic.
2 ug-like features required for development as pharmacotherapeutics.
3 posed to tissue-selective-and gender-neutral pharmacotherapeutics.
4 for which there are no universally effective pharmacotherapeutics.
5 be possible, facilitating the development of pharmacotherapeutics.
6 s, for which we currently have few effective pharmacotherapeutics.
7 otransmission and their potential utility as pharmacotherapeutics.
8 try that forms the basis for the majority of pharmacotherapeutics.
9 ure progression and are targeted by standard pharmacotherapeutics.
10 echanisms could represent a new paradigm for pharmacotherapeutics.
11 007 as a lead for discovery of cocaine-abuse pharmacotherapeutics.
12 ence lifestyle modifications and advances in pharmacotherapeutics, a large percentage of patients sti
13 D risk factors, AD preclinical detection and pharmacotherapeutic action of AD symptoms.
14 a rapid timescale and also suggests that the pharmacotherapeutic actions of amphetamine for cocaine a
15 , and patients, yet the relevance of this to pharmacotherapeutic actions remains unresolved.
16          Our results demonstrate that an ASO pharmacotherapeutic administered to a developing organ s
17 m with a rising incidence and morbidity, few pharmacotherapeutic advances have been made over the pas
18 h indicated its potential in developing as a pharmacotherapeutic against elastase-mediated pathologie
19                      A diagnostic trial of a pharmacotherapeutic agent could be started in people wit
20  existing therapy has started the search for pharmacotherapeutic agents acting on alternative pathway
21       GBR-12909-like compounds may be useful pharmacotherapeutic agents for cocaine addiction.
22 ective benzyl phenylacetamides are candidate pharmacotherapeutic agents that could be used to minimiz
23  the mechanisms, risk factors, and offending pharmacotherapeutic agents that may cause drug-induced a
24  combination therapy and introduction of new pharmacotherapeutic agents.
25                                        Thus, pharmacotherapeutics aimed at enhancing cognitive functi
26 ith reduced cocaine intake, and propose that pharmacotherapeutics aimed at these complexes may have p
27 d glucose balance with current and potential pharmacotherapeutic and surgical interventions for the t
28 anisms should facilitate the design of novel pharmacotherapeutics and dedicated antidiabetes GI manip
29 fic risk, and the effects of atherosclerosis pharmacotherapeutics and devices.
30 nvasive imaging technology and data on novel pharmacotherapeutics and other therapeutic interventions
31 epidemiological, neuroimaging, pathological, pharmacotherapeutic, and clinical studies.
32 -line therapy, inhaled GM-CSF is a promising pharmacotherapeutic approach demonstrated in well-contro
33          Moreover, PDM may represent a novel pharmacotherapeutic approach for cocaine addiction becau
34             Herein, we target obesity with a pharmacotherapeutic approach that decreases caloric effi
35 transformation and suggest a potential novel pharmacotherapeutic approach to acute myeloid leukaemia.
36 ion in mitochondria may represent a rational pharmacotherapeutic approach to diseases with increased
37  for multiple sclerosis can provide a viable pharmacotherapeutic approach to reduce neuro-immune cell
38 d pneumonia, should be treated with evolving pharmacotherapeutic approaches as appropriate, including
39                               Behavioral and pharmacotherapeutic approaches constitute two prominent
40                                              Pharmacotherapeutic approaches for cancer therapy-induce
41 and peripheral circulations, and traditional pharmacotherapeutic approaches have not significantly af
42 n opens new directions in the development of pharmacotherapeutic approaches in the management of CHB.
43                                              Pharmacotherapeutic approaches limiting changes in KOPr/
44 f MIF in viral pathogenesis and suggest that pharmacotherapeutic approaches targeting MIF may hold pr
45 uture development of novel anti-inflammatory pharmacotherapeutic approaches to combat respiratory dis
46 ne axis in SSADH(-/-) mouse brain, effective pharmacotherapeutic approaches, preliminary gene-therapy
47 ology and even open new avenues for targeted pharmacotherapeutic approaches.
48 of the disease pathophysiology and alternate pharmacotherapeutic approaches.
49 y constitute a target for new diagnostic and pharmacotherapeutic approaches.
50                                           No pharmacotherapeutics are available to treat CAVD because
51 diseases with the E-pore peptide opens novel pharmacotherapeutic avenues in the diagnosis and managem
52    There is a critical need to develop novel pharmacotherapeutics capable of addressing the positive,
53                          Standard courses of pharmacotherapeutic cessation aids improve short-term ab
54              Sociodemographic, clinical, and pharmacotherapeutic data were collected from 101 patient
55  and represent a promising target for future pharmacotherapeutic development of Y1 agonists.
56 lding blocks for generating novel HS mimetic pharmacotherapeutics, diagnostic reagents, and biomateri
57  vivo, which led to a clear light-controlled pharmacotherapeutic effect on mouse skin lesions.
58 l, cannabidiol (CBD), has been shown to have pharmacotherapeutic efficacy for the treatment of schizo
59         Results from this study suggest that pharmacotherapeutic efficacy in schizophrenia treatment
60 g trauma and sepsis and in the assessment of pharmacotherapeutic efficacy.
61 ially, new leads toward the development of a pharmacotherapeutic for cocaine abuse and other disorder
62  of the genes encoding targets of first-line pharmacotherapeutics for ADHD were significantly associa
63 tyle interventions, including more effective pharmacotherapeutics for obesity, offer hope to patients
64 ntagonists have been implicated as potential pharmacotherapeutics for the treatment of cocaine abuse.
65 elp identify novel diagnostic biomarkers and pharmacotherapeutics for these disorders.
66  of alpha4beta2-nAChR can potentially be new pharmacotherapeutics for treatment of nicotine dependenc
67 ulation of axonal Ca(2+) stores may be a key pharmacotherapeutic goal in spinal cord injury.
68 acogenomic (PGx) testing provides preemptive pharmacotherapeutic guidance regarding the lack of thera
69                 Such oligonucleotide-derived pharmacotherapeutics have limitations in specificity for
70 nd focus on the early initiation of multiple pharmacotherapeutics in appropriate patients.
71                           Current narcolepsy pharmacotherapeutics include controlled substances with
72  receptors (KORs) is highly anticipated as a pharmacotherapeutic intervention for substance use disor
73 e behavioral pathologies and as a target for pharmacotherapeutic intervention in comorbid AUD and BE
74 otein SAP97 may represent a novel target for pharmacotherapeutic intervention in the treatment of coc
75        The combined cognitive-behavioral and pharmacotherapeutic intervention resulted in sustained a
76 is of the disease and offers new targets for pharmacotherapeutic intervention.
77             Clinical trials designed to test pharmacotherapeutic interventions (including anti-dement
78 clinical trials to test novel strategies and pharmacotherapeutic interventions for acute or delayed n
79        Several clinical trials testing novel pharmacotherapeutic interventions for the management of
80  is an important clinical need, but specific pharmacotherapeutic interventions for this phase of illn
81 currently unknown to what order of magnitude pharmacotherapeutic interventions may induce changes in
82                      Intensive lifestyle and pharmacotherapeutic interventions reduce the progression
83                 Clinical trials for proposed pharmacotherapeutic interventions to help manage these c
84 ing, requires constant psychotherapeutic and pharmacotherapeutic interventions to minimize the potent
85 ial alternatives to current psychosocial and pharmacotherapeutic interventions, but identification of
86  the development of more targeted, effective pharmacotherapeutic interventions.
87 ms discovered in model organisms may lead to pharmacotherapeutic interventions.
88 not target opioid receptors or common opioid pharmacotherapeutics, it can be used in conjunction with
89 crease in Abeta secretion and respond to the pharmacotherapeutic modulation by anti-amyloidogenic com
90 ing this gatekeeper function may provide new pharmacotherapeutic opportunities to prevent the excessi
91 etiology of autism, few have translated into pharmacotherapeutic opportunities.
92 regulator that is also being considered as a pharmacotherapeutic option for obesity and type 2 diabet
93  activation of PPARgamma may represent a new pharmacotherapeutic option for the treatment of opioid a
94 ess, leaving this patient population without pharmacotherapeutic options.
95  consists of androgen deprivation therapy by pharmacotherapeutic or surgical means.
96 physician's discretion, assisted by hospital pharmacotherapeutic or transfusion committees.
97 sed nanostructured systems for improving the pharmacotherapeutic performance of phytomedicines for ca
98 onships between common genetic variation and pharmacotherapeutic phenotypes.
99                   The synthesized compounds' pharmacotherapeutic potential has been evaluated, employ
100                         The data support the pharmacotherapeutic potential of PEDF as a neuroprotecta
101             Interventions such as aggressive pharmacotherapeutic prophylaxis to prevent relapse or re
102 y ill patients are treated with an extensive pharmacotherapeutic regimen.
103 but GC treatment may be associated with poor pharmacotherapeutic response or prognosis.
104 efore, may prove to be a putative target for pharmacotherapeutic strategies and cognitive-behavioral
105 ed, it is imperative that safe and effective pharmacotherapeutic strategies are rapidly explored to i
106                  Moreover, it suggests novel pharmacotherapeutic strategies for osteoporosis and, per
107 ns, emphasizing the importance of innovative pharmacotherapeutic strategies in addressing the burden
108                                     Gene and pharmacotherapeutic strategies to rescue auditory functi
109               Mifepristone may be a valuable pharmacotherapeutic strategy for preventing relapse to a
110 s in Alzheimer's disease (AD) is an emerging pharmacotherapeutic strategy.
111 ocarbon receptor (AhR) is a highly pertinent pharmacotherapeutic strategy.
112                                       First, pharmacotherapeutic studies using pancreatic tumor cell
113 disease and at the same time provide a novel pharmacotherapeutic target for a lung disease that to da
114 P-1R) has begun to be studied as a potential pharmacotherapeutic target for alcohol use disorder (AUD
115 h, the results identify group II mGluRs as a pharmacotherapeutic target for craving and relapse preve
116 coupled receptors (GPCRs) and is a potential pharmacotherapeutic target for heart failure, hypertensi
117 y mediator of coronary vascular repair and a pharmacotherapeutic target for immune-mediated injury of
118 tify the integrin alpha9beta1 as a potential pharmacotherapeutic target for inhibition of pathogenic
119 ygenic risk for PTSD and suggest a potential pharmacotherapeutic target for risk genes moderated by s
120         Thus, ADAM10 represents an important pharmacotherapeutic target for the treatment of cerebral
121 line receptor is suggested to be a potential pharmacotherapeutic target for the treatment of drug abu
122   These findings implicate Na(V)1.7 as a key pharmacotherapeutic target for the treatment of pain.
123  receptor (D(3)R) has emerged as a promising pharmacotherapeutic target for the treatment of several
124 se in microglia-enriched CD11b(+) cells as a pharmacotherapeutic target implicated in the pathophysio
125 hypothesis that KORs may provide a promising pharmacotherapeutic target in the treatment of alcoholis
126 H2 is hence considered an important emerging pharmacotherapeutic target, the role of the DP receptor
127 er drugs, rendering this pathway a promising pharmacotherapeutic target.
128 ne injury in general, it forms an attractive pharmacotherapeutic target.
129 ase pathway of anandamide synthesis may be a pharmacotherapeutic target.
130  in the nucleus accumbens (NAc) as potential pharmacotherapeutic targets for treating cocaine additio
131       Ion channels are thus a major class of pharmacotherapeutic targets.
132 way-selective modulation can enable improved pharmacotherapeutics that can promote therapeutic effica
133 ous substrates should aid the development of pharmacotherapeutics that target individual MMPs.
134  reported these add-on therapies to be novel pharmacotherapeutic therapies in patients with NAFLD and
135  opioid ligands may be useful as a potential pharmacotherapeutic to decrease drug abuse.
136 ogy, gene therapy, cell cycle regulation and pharmacotherapeutics to define and validate regenerative
137 h there are no effective novel or repurposed pharmacotherapeutics to prevent disease progression.
138 is a promising target for the development of pharmacotherapeutics to treat substance use disorders.
139                      Recent successes in the pharmacotherapeutic treatment of breast cancer are assoc
140  homeostasis represent viable candidates for pharmacotherapeutic treatment of psychostimulant relapse
141 iplatelet agents necessary components of the pharmacotherapeutic treatment paradigm for these patient
142                           The development of pharmacotherapeutic treatments of psychostimulant abuse
143  should be considered as an outcome in acute pharmacotherapeutic trials for COVID-19.
144 the goal of developing potential Alzheimer's pharmacotherapeutics, we have synthesized a series of no

 
Page Top